DECURSINOL-50®

---

​From the study results, we have estimated that the LD50 of Decursinol-50® in rats is 3,722 mg/Kg for males and 2,804 mg/Kg for females.

Investigations of 4-week repeat-dose toxicity of Decursinol-50® in SD rats did not find any significant toxicological changes in the high dose group (500mg/Kg), though it did find a 10% loss of body weight compared to the control group. The maximum tolerable dose of the test material is therefore below 500 mg/Kg, while the non-toxic dose level is above 100 mg/Kg. From these results, Decursinol-50® is considered to be highly appropriate for human use. 

• All animals survived the test period
• No clinical abnormalities were found across all dose level and all animals
• No abnormalities were observed across all test groups, including the control group
• No abnormalities were observed in the urine analyses across all test groups, including the control group
• No abnormalities were observed in the necropsy gross findings across all test groups, including the control group

1. "Antinociceptive Profiles of Crude Extract from Roots of Angelica gigas NAKAI in Various Pain Models," Biological and Pharmaceutical Bulletin, 26(9), 1283-1288 (2003).

2. "Antinociceptive mechanisms of orally administered decursinol in the mouse," Life Sciences, 73(4), 471-85 (2003).

3. "Oral Acute and Subacute Toxicity Studies of Decursin and Decursinol Angelate of Angelica gigas Nakai," Molecular & Cellular Toxicology, 5(2), 153-159 (2009).